Sildenafil

Drug Profile

Sildenafil

Alternative Names: Revatio; Revatio IV; Sildenafil citrate; UK 92480; Viagra

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heart failure; Pulmonary hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erectile dysfunction; Pulmonary hypertension
  • Phase III Heart failure
  • Clinical Phase Unknown Female infertility; Raynaud's disease
  • Discontinued Angina pectoris; Cardiovascular disorders; Eye disorders; Female sexual dysfunction

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2014 Pfizer and University Medical Centre Groningen complete a phase III trial in Heart failure and Pulmonary hypertension in the Netherlands (NCT01726049)
  • 01 Jul 2013 Phase-III clinical trials in Pulmonary hypertension (neonates) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top